Clinical Trial

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2026-06 -> 2027-10-24 2026-07-19
minor Completion pushed: 2026-10 -> 2029-10-23 2026-07-19
notable Trial sites expanded: 36 -> 42 locations 2026-06-12
notable Trial sites expanded: 32 -> 36 locations 2026-05-13
Trial Details
NCT Number NCT06638307
Lead Sponsor Stemline Therapeutics, Inc.
Conditions Advanced Breast Cancer
Enrollment 240 participants
Start Date 2024-10-25
Primary Completion 2027-10-24 (estimated)
Study Completion 2029-10-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-07